Inhibition of Streptococcus pneumoniae adherence to human epithelial cells in vitro by the probiotic Lactobacillus rhamnosus GG

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Wong, Sook San ^a,e   Quan Toh, Zheng ^a   Dunne, Eileen M ^a   Mulholland, E Kim ^a,b,c   Tang, Mimi L K ^a,d   Robins Browne, Roy M ^a,d   Licciardi, Paul V ^a   Satzke, Catherine ^a,d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Colonization; in vitro model; LGG; Pneumococci; Probiotic

Indexed keywords

BACTERIA (MICROORGANISMS); LACTOBACILLUS RHAMNOSUS; STREPTOCOCCUS PNEUMONIAE;

CHEMOKINE; CYTOKINE; PROBIOTIC AGENT;

ARTICLE; BACTERIUM ADHERENCE; CELL CULTURE; CYTOLOGY; EPITHELIUM CELL; GROWTH, DEVELOPMENT AND AGING; HUMAN; LACTOBACILLUS RHAMNOSUS; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; STEM CELL; STREPTOCOCCUS PNEUMONIAE;

BACTERIAL ADHESION; CELLS, CULTURED; CHEMOKINES; CYTOKINES; EPITHELIAL CELLS; HUMANS; LACTOBACILLUS RHAMNOSUS; PROBIOTICS; STEM CELLS; STREPTOCOCCUS PNEUMONIAE;

EID: 84875823963     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-135     Document Type: Article

References (46)

1. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T, Lancet 2009 374 9693 893 902 10.1016/S0140-6736(09)61204-6 19748398
2. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. Gray BM, Converse GM 3rd, Dillon HC Jr, J Infect Dis 1980 142 6 923 933 10.1093/infdis/142.6.923 7462701
3. Early acquisition and high nasopharyngeal co-colonisation by Streptococcus pneumoniae and three respiratory pathogens amongst Gambian new-borns and infants. Kwambana BA, Barer MR, Bottomley C, Adegbola RA, Antonio M, BMC Infect Dis 2011 11 175 10.1186/1471-2334-11-175 21689403
4. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, Muenz LR, O'Brien KL, PLoS Med 2010 7 10 1000348 10.1371/journal.pmed.1000348 20957191
5. Serotype replacement after pneumococcal vaccination. Mulholland K, Satzke C, Lancet 2012 379 9824 1387 22500869
6. FAO/WHO 2001, Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria Cordoba, Argentina 2001 1 to 4 October
7. Probiotics, infection and immunity. Macfarlane GT, Cummings JH, Curr Opin Infect Dis 2002 15 5 501 506 10.1097/00001432-200210000-00008 12686883
8. Probiotics and gastrointestinal diseases. Sullivan A, Nord CE, J Intern Med 2005 257 1 78 92 10.1111/j.1365-2796.2004.01410.x 15606379
9. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Collado MC, Meriluoto J, Salminen S, Lett Appl Microbiol 2007 45 4 454 460 10.1111/j.1472-765X.2007.02212.x 17897389
10. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. Jeon SG, Kayama H, Ueda Y, Takahashi T, Asahara T, Tsuji H, Tsuji NM, Kiyono H, Ma JS, Kusu T, PLoS Pathog 2012 8 5 1002714 10.1371/journal.ppat. 1002714 22693446
11. Lactobacillus plantarum DSM 2648 is a potential probiotic that enhances intestinal barrier function. Anderson RC, Cookson AL, McNabb WC, Kelly WJ, Roy NC, FEMS Microbiol Lett 2010 309 2 184 192 20618863
12. Protecting against pneumococcal disease: critical interactions between probiotics and the airway microbiome. Licciardi PV, Toh ZQ, Dunne E, Wong SS, Mulholland EK, Tang M, Robins-Browne RM, Satzke C, PLoS Pathog 2012 8 6 1002652 10.1371/journal.ppat.1002652 22685396
13. Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens. Popova M, Molimard P, Courau S, Crociani J, Dufour C, Le Vacon F, Carton T, J Appl Microbiol 2012 113 6 1305 1318 10.1111/j.1365-2672.2012.05394.x 22788970
14. Lactobacillus pentosus strain b240 suppresses pneumonia induced by Streptococcus pneumoniae in mice. Tanaka A, Seki M, Yamahira S, Noguchi H, Kosai K, Toba M, Morinaga Y, Miyazaki T, Izumikawa K, Kakeya H, Lett Appl Microbiol 2011 53 1 35 43 10.1111/j.1472-765X.2011.03079.x 21554343
15. Lactobacillus casei administration reduces lung injuries in a Streptococcus pneumoniae infection in mice. Racedo S, Villena J, Medina M, Aguero G, Rodriguez V, Alvarez S, Microbes Infect 2006 8 9-10 2359 2366 16904925
16. Nasal administration of Lactococcus lactis improves local and systemic immune responses against Streptococcus pneumoniae. Medina M, Villena J, Salva S, Vintini E, Langella P, Alvarez S, Microbiol Immunol 2008 52 8 399 409 10.1111/j.1348-0421.2008.00050.x 18667039
17. Lactobacillus rhamnosus GG inhibits invasion of cultured human respiratory cells by prtF1-positive macrolide-resistant group A streptococci. Princivalli MS, Paoletti C, Magi G, Palmieri C, Ferrante L, Facinelli B, Lett Appl Microbiol 2009 48 3 368 372 10.1111/j.1472-765X.2008.02540.x 19187508
18. Ingested probiotics reduce nasal colonization with pathogenic bacteria (Staphylococcus aureus, Streptococcus pneumoniae, and beta-hemolytic streptococci). Gluck U, Gebbers JO, Am J Clin Nutr 2003 77 2 517 520 12540416
19. Involvement of glycosaminoglycans in the attachment of pneumococci to nasopharyngeal epithelial cells. Tonnaer EL, Hafmans TG, Van Kuppevelt TH, Sanders EA, Verweij PE, Curfs JH, Microbes Infect 2006 8 2 316 322 10.1016/j.micinf.2005.06.028 16239116
20. Adherence of Streptococcus pneumoniae to polystyrene plates and epithelial cells and the antiadhesive potential of albumin and xylitol. Ruiz V, Rodriguez-Cerrato V, Huelves L, Del Prado G, Naves P, Ponte C, Soriano F, Pediatr Res 2011 69 1 23 27 10.1203/PDR.0b013e3181fed2b0 20885335
21. Binding characteristics of the Lactobacillus brevis ATCC 8287 surface layer to extracellular matrix proteins. de Leeuw E, Li X, Lu W, FEMS Microbiol Lett 2006 260 2 210 215 10.1111/j.1574-6968.2006.00313.x 16842346
22. Lactobacilli express cell surface proteins which mediate binding of immobilized collagen and fibronectin. Lorca G, Torino MI, Font de Valdez G, Ljungh AA, FEMS Microbiol Lett 2002 206 1 31 37 10.1111/j.1574-6968.2002. tb10982.x 11786253
23. PfbA, a novel plasmin- and fibronectin-binding protein of Streptococcus pneumoniae, contributes to fibronectin-dependent adhesion and antiphagocytosis. Yamaguchi M, Terao Y, Mori Y, Hamada S, Kawabata S, J Biol Chem 2008 283 52 36272 36279 10.1074/jbc.M807087200 18974092
24. The streptococcal lipoprotein rotamase A (SlrA) is a functional peptidyl-prolyl isomerase involved in pneumococcal colonization. Hermans PW, Adrian PV, Albert C, Estevao S, Hoogenboezem T, Luijendijk IH, Kamphausen T, Hammerschmidt S, J Biol Chem 2006 281 2 968 976 16260779
25. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Spinler JK, Taweechotipatr M, Rognerud CL, Ou CN, Tumwasorn S, Versalovic J, Anaerobe 2008 14 3 166 171 10.1016/j.anaerobe.2008.02.001 18396068
26. Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Wescombe PA, Heng NC, Burton JP, Chilcott CN, Tagg JR, Future Microbiol 2009 4 7 819 835 10.2217/fmb.09.61 19722837
27. Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Bergeron Y, Ouellet N, Deslauriers AM, Simard M, Olivier M, Bergeron MG, Infect Immun 1998 66 3 912 922 9488375
28. Modulation of the inflammatory response to Streptococcus pneumoniae in a model of acute lung tissue infection. Xu F, Droemann D, Rupp J, Shen H, Wu X, Goldmann T, Hippenstiel S, Zabel P, Dalhoff K, Am J Respr Cell Mol Biol 2008 39 5 522 529 10.1165/rcmb.2007-0328OC
29. Serum interleukin-6 in bacterial and nonbacterial acute otitis media. Heikkinen T, Ghaffar F, Okorodudu AO, Chonmaitree T, Pediatr 1998 102 2 Pt 1 296 299
30. Streptococcus pneumoniae induced c-Jun-N-terminal kinase- and AP-1 -dependent IL-8 release by lung epithelial BEAS-2B cells. Schmeck B, Moog K, Zahlten J, van Laak V, N'Guessan PD, Opitz B, Rosseau S, Suttorp N, Hippenstiel S, Respir Res 2006 7 98 10.1186/1465-9921-7-98 16834785
31. Evaluation of Lactobacillus rhamnosus GG using an Escherichia coli K88 model of piglet diarrhoea: Effects on diarrhoea incidence, faecal microflora and immune responses. Zhang L, Xu YQ, Liu HY, Lai T, Ma JL, Wang JF, Zhu YH, Vet Microbiol 2010 141 1-2 142 148 19782483
32. Porcine small intestinal epithelial cell line (IPEC-J2) of rotavirus infection as a new model for the study of innate immune responses to rotaviruses and probiotics. Liu F, Li G, Wen K, Bui T, Cao D, Zhang Y, Yuan L, Viral Immunol 2010 23 2 135 149 10.1089/vim.2009.0088 20373994
33. Effect of Vibrio cholerae on chemokine gene expression in HT29 cells and its modulation by Lactobacillus GG. Nandakumar NS, Pugazhendhi S, Madhu Mohan K, Jayakanthan K, Ramakrishna BS, Scand J Immunol 2009 69 3 181 187 10.1111/j.1365-3083.2008.02214.x 19281529
34. Live and ultraviolet-inactivated Lactobacillus rhamnosus GG decrease flagellin-induced interleukin-8 production in Caco-2 cells. Lopez M, Li N, Kataria J, Russell M, Neu J, J Nutr 2008 138 11 2264 2268 10.3945/jn.108.093658 18936229
35. Interleukin-1beta regulates CXCL8 release and influences disease outcome in response to Streptococcus pneumoniae, defining intercellular cooperation between pulmonary epithelial cells and macrophages. Marriott HM, Gascoyne KA, Gowda R, Geary I, Nicklin MJ, Iannelli F, Pozzi G, Mitchell TJ, Whyte MK, Sabroe I, Infect Immun 2012 80 3 1140 1149 10.1128/IAI.05697-11 22158745
36. Structural diversity of heparan sulfate binding domains in chemokines. Lortat-Jacob H, Grosdidier A, Imberty A, Proc Natl Acad Sci USA 2002 99 3 1229 1234 10.1073/pnas.032497699 11830659
37. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Webb LM, Ehrengruber MU, Clark-Lewis I, Baggiolini M, Rot A, Proc Natl Acad Sci USA 1993 90 15 7158 7162 10.1073/pnas.90.15.7158 8346230
38. Specific probiotics in reducing the risk of acute infections in infancy-a randomised, double-blind, placebo-controlled study. Rautava S, Salminen S, Isolauri E, Br J Nutr 2009 101 11 1722 1726 10.1017/S0007114508116282 18986600
39. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Kuitunen M, Pediatr 2008 122 1 8 12 10.1542/peds.2007-1192
40. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Hojsak I, Abdovic S, Szajewska H, Milosevic M, Krznaric Z, Kolacek S, Pediatr 2010 125 5 1171 1177 10.1542/peds.2009-2568
41. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Hojsak I, Snovak N, Abdovic S, Szajewska H, Misak Z, Kolacek S, Clin Nutr 2010 29 3 312 316 10.1016/j.clnu.2009.09.008 19896252
42. Treatment of acute otitis media with probiotics in otitis-prone children-a double-blind, placebo-controlled randomised study. Hatakka K, Blomgren K, Pohjavuori S, Kaijalainen T, Poussa T, Leinonen M, Korpela R, Pitkaranta A, Clin Nutr 2007 26 3 314 321 10.1016/j.clnu.2007.01.003 17353072
43. Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Skovbjerg S, Roos K, Holm SE, Grahn Hakansson E, Nowrouzian F, Ivarsson M, Adlerberth I, Wold AE, Arch Dis Child 2009 94 2 92 98 10.1136/adc.2008.141002 18713796
44. Immunomodulatory mechanisms of lactobacilli. Wells JM, Microb Cell Fact 2011 10 Suppl 1 17 10.1186/1475-2859-10-S1-S17 21995674
45. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T, Vaccine 1995 13 3 310 312 10.1016/0264-410X(95)93319-5 7631519
46. Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? Walls T, Power D, Tagg J, J Med Microbiol 2003 52 Pt 9 829 833 12909662